Company guidance, FDA catalysts, dilution risk and cash runway, built from SEC, FDA and ClinicalTrials.gov filings and updated every day.
We send one confirmation email first. Only emails about LIMN, unsubscribe in one click. Privacy
LIMN holds $3M in cash and short-term investments (as of Jun 30, 2026) and burns about $1.5M/quarter from operations, an estimated runway of 6.1 months at that rate (BioRadar estimate, not company guidance).
Dilution pressure: 55 · Elevated
In connection with the Company’s assessment of going concern considerations in accordance with Financial Accounting Standards Board (“FASB”) ASC 205-40, Presentation of Financial Statements—Going Concern , management has concluded that there is substantial doubt about its ability to continue as a going concern for one10-Q, Aug 2026
Recent financing filings on SEC EDGAR:
Source: SEC EDGAR (XBRL cash flow and financing filings). Dilution Watch: every company ranked → · Get an alert when LIMN files for a raise →
The 7-day free trial adds AI daily briefings, sentiment tracking, trial enrollment progress and email alerts for LIMN and every other ticker you follow. Card required, cancel anytime.
Start 7-day free trial →